Immediate Causes of Death in Thyroid Carcinoma: Clinicopathological Analysis of 161 Fatal Cases
Yutaka Kitamura,
Kazuo Shimizu,
Mitsuji Nagahama,
Kiminori Sugino,
Osamu Ozaki,
Takashi Mimura,
Kunihiko Ito,
Koichi Ito and
Shigeo Tanaka
Department of Surgery II, Nippon Medical School (Y.K., K.Sh.,
S.T.), 11-5 Sendagi, Bunkyo-ku, Tokyo 113; and the Surgery Branch,
Ito Hospital (M.N., K.Su., O.O., T.M., Ku.I., Ko.I.), 43-6 Jingumae,
Shibuya-ku, Tokyo 150, Japan
Address all correspondence and requests for reprints to: Yutaka Kitamura, M.D., Department of Surgery II, Nippon Medical School, 11-5 Sendagi, Bunkyo-ku, Tokyo 113, Japan. E-mail: taka{at}nms.ac.jp
Most patients with thyroid carcinoma have a good prognosis.Due to the
small number of fatal cases, it has not been clarifiedwhat conditions
result in death for patients with thyroid carcinoma.To provide
appropriate management for advanced thyroid carcinomapatients, we
analyzed causes of death in 161 fatal cases. Clinicalcharacteristics
and immediate (final) causes of death basedon pathological conditions
were analyzed in 62 anaplastic carcinomasand 99 fatal differentiated
carcinomas. Single fatal conditionscould not be specified in 55
patients. In the remaining 106patients, respiratory insufficiency
(43%) was the most commonspecific fatal condition, followed by
circulatory failure (15%),hemorrhage (15%), and airway obstruction
(13%). Respiratoryinsufficiency due to remarkable pulmonary
metastasis replacinglung tissue, massive hemorrhage and airway
obstruction due touncontrolled local tumors, and circulatory failure
resultingfrom compression of the vena cava by extensive mediastinal or
sternalmetastases were found to be the most important immediate causes
ofdeath. Based on this knowledge, several palliative proceduresmay be
worth considering to improve survival and quality oflife in patients
with advanced thyroid carcinoma.
This article has been cited by other articles:
M. TULLOCH-REID, M. C. SKARULIS, S. I. SHERMAN, N. J. SARLIS, and L. SANTARPIA Long-term Eradication of Locally Recurrent Invasive Follicular Thyroid Carcinoma after Taxane-based Concomitant Chemoradiotherapy
Anticancer Res,
November 1, 2009;
29(11):
4665 - 4671.
[Abstract][Full Text][PDF]
K. Sakano, M. Takahashi, M. Mutoh, N. Niho, M. Komiya, H. Sato, T. Tanaka, T. Sugimura, and K. Wakabayashi Enhanced thyroid carcinogenicity of N-nitrosobis(2-oxopropyl)amine in Otsuka Long-Evans Tokushima Fatty rats, a model of type II diabetes mellitus
Carcinogenesis,
October 1, 2007;
28(10):
2193 - 2198.
[Abstract][Full Text][PDF]
E. Brignardello, M. Gallo, I. Baldi, N. Palestini, A. Piovesan, E. Grossi, G. Ciccone, and G. Boccuzzi Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years
Eur. J. Endocrinol.,
April 1, 2007;
156(4):
425 - 430.
[Abstract][Full Text][PDF]
M. G Catalano, N. Fortunati, M. Pugliese, R. Poli, O. Bosco, R. Mastrocola, M. Aragno, and G. Boccuzzi Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
J. Endocrinol.,
November 1, 2006;
191(2):
465 - 472.
[Abstract][Full Text][PDF]
C. Saez, M. A. Martinez-Brocca, C. Castilla, A. Soto, E. Navarro, M. Tortolero, J. A. Pintor-Toro, and M. A. Japon Prognostic Significance of Human Pituitary Tumor-Transforming Gene Immunohistochemical Expression in Differentiated Thyroid Cancer
J. Clin. Endocrinol. Metab.,
April 1, 2006;
91(4):
1404 - 1409.
[Abstract][Full Text][PDF]
C. F. A. Eustatia-Rutten, E. P. M. Corssmit, N. R. Biermasz, A. M. Pereira, J. A. Romijn, and J. W. Smit Survival and Death Causes in Differentiated Thyroid Carcinoma
J. Clin. Endocrinol. Metab.,
January 1, 2006;
91(1):
313 - 319.
[Abstract][Full Text][PDF]
S. B. Bravo, M. E.R. Garcia-Rendueles, R. Seoane, V. Dosil, J. Cameselle-Teijeiro, L. Lopez-Lazaro, J. Zalvide, F. Barreiro, C. M. Pombo, and C. V. Alvarez Plitidepsin Has a Cytostatic Effect in Human Undifferentiated (Anaplastic) Thyroid Carcinoma
Clin. Cancer Res.,
November 1, 2005;
11(21):
7664 - 7673.
[Abstract][Full Text][PDF]
A. Rouxel, G. Hejblum, M.-O. Bernier, P.-Y. Boelle, F. Menegaux, G. Mansour, C. Hoang, A. Aurengo, and L. Leenhardt Prognostic Factors Associated with the Survival of Patients Developing Loco-Regional Recurrences of Differentiated Thyroid Carcinomas
J. Clin. Endocrinol. Metab.,
November 1, 2004;
89(11):
5362 - 5368.
[Abstract][Full Text][PDF]
E. L. Mazzaferri and R. T. Kloos Is Diagnostic Iodine-131 Scanning with Recombinant Human TSH Useful in the Follow-Up of Differentiated Thyroid Cancer after Thyroid Ablation?
J. Clin. Endocrinol. Metab.,
April 1, 2002;
87(4):
1490 - 1498.
[Abstract][Full Text][PDF]
Y. Kitamura, K. Shimizu, K. Ito, S. Tanaka, and M. Emi Allelotyping of Follicular Thyroid Carcinoma: Frequent Allelic Losses in Chromosome Arms 7q, 11p, and 22q
J. Clin. Endocrinol. Metab.,
September 1, 2001;
86(9):
4268 - 4272.
[Abstract][Full Text][PDF]
E. L. Mazzaferri and R. T. Kloos Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer
J. Clin. Endocrinol. Metab.,
April 1, 2001;
86(4):
1447 - 1463.
[Full Text]